ISDA: 4F09

Deposition Date 2012-05-03

Release Date 2012-07-04

Last Version Date 2024-11-06

Entry Detail

PDB ID:

4F09

Keywords:

TRANSFERASE/TRANSFERASE INHIBITOR

Title:

Discovery and Optimization of C-2 Methyl Imidazo-pyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2

Biological Source:

Source Organism(s):

Homo sapiens (Taxon ID: 9606)

Expression System(s):

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.40 Å

R-Value Free:

0.25

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Tyrosine-protein kinase JAK2
Gene (Uniprot):JAK2
Chain IDs:A
Chain Length:302
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:O60674 Pfam ID:PF07714 EC:2.7.10.2

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
PTR	A	TYR	O-PHOSPHOTYROSINE

Ligand Molecules

JAK

Primary Citation

Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2.

Zak, M, Mendonca, R, Balazs, M, Barrett, K, Bergeron, P, Blair, W.S, Chang, C, Deshmukh, G, Devoss, J, Dragovich, P.S, Eigenbrot, C, Ghilardi, N, Gibbons, P, Gradl, S, Hamman, C, Hanan, E.J, Harstad, E, Hewitt, P.R, Hurley, C.A, Jin, T, Johnson, A, Johnson, T, Kenny, J.R, Koehler, M.F, Bir Kohli, P, Kulagowski, J.J, Labadie, S, Liao, J, Liimatta, M, Lin, Z, Lupardus, P.J, Maxey, R.J, Murray, J.M, Pulk, R, Rodriguez, M, Savage, S, Shia, S, Steffek, M, Ubhayakar, S, Ultsch, M, van Abbema, A, Ward, S.I, Xiao, L, Xiao, Y.Show

J.Med.Chem. 55 6176 6193 (2012)

PMID: 22698084 DOI: 10.1021/jm300628c

Abstact

Herein we report the discovery of the C-2 methyl substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. The C-2 methyl substituted inhibitor 4 exhibited not only improved JAK1 potency relative to unsubstituted compound 3 but also notable JAK1 vs JAK2 selectivity (20-fold and >33-fold in biochemical and cell-based assays, respectively). Features of the X-ray structures of 4 in complex with both JAK1 and JAK2 are delineated. Efforts to improve the in vitro and in vivo ADME properties of 4 while maintaining JAK1 selectivity are described, culminating in the discovery of a highly optimized and balanced inhibitor (20). Details of the biological characterization of 20 are disclosed including JAK1 vs JAK2 selectivity levels, preclinical in vivo PK profiles, performance in an in vivo JAK1-mediated PK/PD model, and attributes of an X-ray structure in complex with JAK1.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form